6 best EDC platforms for Phase II clinical trials in 2026

Viedoc's EDC software delivers study builds typically completed in 2–4 weeks – a direct contrast to the 90-day standard associated with enterprise platforms – with a no-code Designer your data management team configures in-house, backed by 7,000+ completed studies across 75+ countries and 99.99% platform uptime. This comparison evaluates six leading electronic data capture (EDC) platforms for Phase II clinical trials across study build speed, no-code configurability, compliance credentials, eClinical suite depth, and total cost of ownership.

Phase II is where the operational stakes sharpen. Your protocol is more complex than Phase I – wider patient populations, multi-site enrollment, more endpoints – but you're not yet running the kind of enterprise-scale program that justifies a Medidata Rave implementation timeline measured in quarters. You need a platform that can go live fast, absorb protocol amendments without grinding to a halt, and produce data that's submission-ready when your Phase IIb results land.

What Phase II teams often discover too late is that enterprise platforms were built for Phase III at scale, not for the speed and adaptability Phase II demands. If your current or shortlisted EDC requires a vendor-side programmer for every form change, can't absorb a mid-study amendment within days, or prices by the seat as your study team grows, those constraints compound directly into your budget and your timeline.

Best EDC solutions for Phase II: quick comparison

These six platforms represent the most frequently evaluated EDC options for Phase II clinical trials in 2026, reviewed across study build speed, compliance coverage, configuration model, and eClinical suite depth.

1. Viedoc

Viedoc's EDC software is a cloud-native EDC platform designed for regulated commercial trials across all phases, with particular depth in Phase I and Phase II where study build speed, amendment agility, and cost predictability matter most. The platform has supported 7,000+ studies across 75+ countries, with 1.6 million trial participants managed across 30,000+ sites – a track record that gives Phase II teams confidence in a platform that's been tested in comparable regulatory environments.

For Phase II teams managing protocol amendments mid-study – a near-certainty in any adaptive or dose-escalating program – Viedoc Designer's no-code configuration model is a meaningful operational advantage. Your in-house certified data managers build and amend studies without depending on a vendor-side programmer, which means design changes happen in days rather than the weeks or months that programmer-dependent platforms require. Viedoc's Inspection Readiness Packet (VIRP) is available to all customers at no additional cost, providing structured audit-readiness documentation that accelerates computer system validation (CSV) workflows for QA teams preparing for FDA or EMA scrutiny.

Viedoc is ISO 27001 and SOC 2 certified, hosted on Microsoft Azure, and compliant with 21 CFR Part 11, GDPR, EU Annex 11, HIPAA, and ICH GCP – the full regulatory stack a Phase II sponsor or CRO needs to operate across US and EU markets. The platform is available in 40+ languages across 75+ countries, supported by 24/7 customer success with direct escalation paths rather than ticket-only queues.

"Data handling, reviews, UAT, query management and the monitoring is a walk in the park, which makes it stand out from other EDCs." – Deekshitha V., Mid Market, verified Viedoc user on G2

• Study scale: 7,000+ studies run on Viedoc across 75+ countries
• User base: 140,000+ users globally; 30,000+ sites; 1.6 million trial participants
• Build speed: Study builds typically completed in 2–4 weeks
• Uptime: 99.99% platform uptime; hosted on Microsoft Azure
• Compliance: 21 CFR Part 11, GDPR, EU Annex 11, HIPAA; ISO 27001 and SOC 2 certified
• Inspection readiness: Viedoc Inspection Readiness Packet (VIRP) available to all customers at no additional cost
• Pricing: Unlimited user seats; no per-user fees; transparent, study-based licensing
• No-code designer: Studies configured in-house by certified data managers; no vendor-side programmer required

Launch, manage, and monitor clinical trials faster with intuitive EDC clinical trial software that keeps you compliant and audit ready.

2. Medidata

Medidata offers Rave EDC, a cloud-based EDC platform deployed in over 36,000 trials globally and embedded as the standard system for large pharma Phase III programs. Rave EDC provides deep integrations across the Medidata Clinical Cloud, connecting data capture with randomization, patient outcome collection, and safety modules in a unified enterprise architecture. The platform is highly configurable for complex, multi-site global trial designs – including full table-stakes functionality – and carries strong regulatory credibility among FDA-facing procurement teams. Study builds and amendments typically require substantial programming resource and extended timelines that reflect the platform's enterprise engineering depth, making it best suited to organizations running high-complexity, high-volume programs where those tradeoffs are acceptable.

3. Veeva Vault EDC

Veeva Vault EDC is a cloud-native EDC module within the Veeva Vault Clinical suite, targeting sponsors who need seamless integration between data capture, eTMF, CTMS, and regulatory information management on a single platform. The solution is positioned primarily for mid-to-large pharma sponsors already operating within the Vault ecosystem, where the suite's unified data model and shared workflows deliver integration benefits that justify the premium pricing model. Vault EDC supports complex study designs and provides a modern interface, though its full value proposition is most realized by organizations buying into the broader Vault platform rather than those seeking standalone EDC capability.

4. Castor EDC

Castor EDC is a no-code, API-first EDC platform with eConsent and ePRO integration built in, primarily targeting CROs, mid-market biotech, and academic institutions running Phase I, II, and real-world evidence (RWE) studies. The platform's intuitive interface and low barrier to entry – including a free academic tier – have built strong brand recognition in the research community, and Castor is increasingly active in regulated Phase II commercial trials. Its module scope is more focused than broader eClinical suites, without native randomization and trial supply management (RTSM) or eTMF, so teams needing those capabilities alongside EDC will typically require additional vendor relationships.

5. Medrio

Medrio offers a mid-market EDC platform with established presence in Phase I and II clinical settings and medical device trials across 100+ countries. The platform is recognized for its accessible interface and offline data capture capability, which is valued in early-phase settings where site connectivity can be variable. Medrio's focused scope covers core EDC data collection and management without the depth of an integrated eClinical suite, and the platform has developed partnerships with specialized vendors for functions such as CTMS, eTMF, and risk-based quality management (RBQM).

6. Oracle InForm

Oracle Health offers Oracle InForm, a long-established enterprise EDC platform with deep roots in global multi-site Phase III trials and integration with Oracle's broader clinical suite covering safety, CTMS, and randomization. InForm carries strong regulatory credibility among large pharma organizations with existing Oracle infrastructure, built through decades of global deployments. The platform is complex to configure, requires specialized technical resource for study setup and amendments, and is architecturally oriented toward large-scale enterprise programs rather than the speed and flexibility that Phase II teams typically prioritize.

What to look for in EDC solutions for Phase II clinical trials

Amendment velocity and in-house control

Phase II protocols change. Adaptive designs, emerging safety signals, and sponsor feedback mid-study mean your EDC platform's amendment workflow isn't a secondary consideration – it's central to whether your timeline holds. The question isn't whether amendments will come; it's how fast your platform can absorb them.

Best-in-class for Phase II means amendments processed in days, not weeks, with your own data management team driving the changes using a no-code interface rather than filing a vendor request and waiting for programming resource. Viedoc's no-code Designer lets certified data managers configure form changes, edit check logic, and visit structures in-house – the kind of amendment agility that protects your FPI date and your sponsor relationship.

Every week of amendment delay at a Phase II site is a week of delayed enrollment – and in an adaptive trial, slow amendments can invalidate the adaptations your protocol was designed to enable.

Compliance coverage for US and EU Phase II submission readiness

Phase II data needs to survive regulatory scrutiny at IND review, protocol amendment filing, and ultimately end-of-Phase II meetings. Your platform's compliance credentials determine how much validation work your QA team carries – and how exposed you are if an FDA or EMA inspector arrives mid-study.

Look for verified compliance with 21 CFR Part 11, ICH GCP, EU Annex 11, and GDPR as a minimum; ISO 27001 and SOC 2 Type II certification for data security; and pre-built audit trail documentation that doesn't require you to build your validation pack from scratch. The availability of structured inspection readiness documentation – such as Viedoc's VIRP – can directly reduce your QA team's CSV burden at study initiation and at every protocol amendment.

Teams that skip thorough compliance diligence at platform selection often spend far more time remediating audit findings than they saved by moving fast at the RFP stage.

Study build speed relative to your FPI commitment

A sponsor's FPI date is a board commitment. A 90-day EDC build timeline stretches FPI by three months before a single patient has been screened. For Phase II, where milestone pressure is at its highest relative to team size, that gap is often commercially unacceptable.

Benchmark: platforms with no-code, drag-and-drop design and CDASH-format template libraries can go live in 2–4 weeks. Programmer-dependent platforms with complex scripting requirements typically take 60–90 days for an equivalent build. Ask vendors for verified reference timelines from comparable Phase II studies – not theoretical minimums – and factor in amendment speed as well as initial build time.

eClinical suite depth and vendor consolidation potential

Phase II often begins with standalone EDC but quickly expands: you add patient-reported outcomes (PRO) data collection as a secondary endpoint, or you need randomization and trial supply management (RTSM) when blinding is introduced in your Phase IIb. Switching EDC platforms mid-program is costly and disruptive – so the question at platform selection is whether your chosen vendor can expand with you.

Look for modular eClinical suites that add ePRO/eCOA software, randomization (RTSM), eTMF software, and medical coding on the same platform without re-validation. Vendor consolidation at Phase II reduces integration overhead and simplifies your audit trail across the trial lifecycle.

Pricing model transparency and total cost of ownership

Enterprise platforms often quote a per-study license figure that undersells the true cost – per-seat fees compound as your study team grows, amendment charges accumulate with every protocol change, and professional services costs for programmer-dependent configurations inflate the implementation budget. Per-seat models are particularly punishing for Phase II teams that expand rapidly as enrollment scales.

A transparent, study-based licensing model with unlimited user seats and no hidden amendment fees gives you cost predictability across the Phase II lifecycle. Confirm what's included in the base license and what triggers additional charges before you sign.

How to choose the right EDC solution for Phase II clinical trials

Step 1: Define your amendment and FPI risk tolerance

Your FPI date and your sponsor's amendment frequency are the two variables that most directly determine which EDC platform category fits your study. If your protocol is complex, adaptive, or likely to generate multiple mid-study amendments, a no-code, in-house-configurable platform will protect your timeline far better than a programmer-dependent system. Establish your tolerance for build and amendment lag before evaluating any vendor on features.

Step 2: Assess your compliance framework against your target markets

US Phase II IND holders need 21 CFR Part 11 compliance and HIPAA attestation at minimum. Multi-country EU studies require GDPR, EU Annex 11, and EMA GCP alignment. Phase II teams targeting Japan or APAC markets need PMDA ERES compliance. Map your regulatory context to each vendor's verified certification list – not their website marketing – before shortlisting.

Step 3: Evaluate whether you need standalone EDC or a modular suite

If your Phase II protocol is purely site-based data capture with no patient-facing components or randomization, standalone EDC may be sufficient. If you're collecting patient-reported outcomes, running a blinded design, or planning to expand into Phase IIb with added complexity, a modular eClinical suite gives you room to grow without changing platforms. Make this decision before you evaluate individual vendors, or you'll find yourself re-evaluating mid-program.

Step 4: Scrutinize validation documentation and QA readiness support

Your QA or CSV team will carry the validation burden for whichever platform you select. Vendors vary significantly in the quality and completeness of their pre-built validation documentation – some provide structured inspection readiness packets that accelerate your IQ/OQ/PQ process; others leave the documentation burden to your own team. This difference in vendor support can translate to weeks of QA resource at study startup and at each amendment.

Step 5: Request verified Phase II reference timelines and choose accordingly

Once you've filtered on compliance credentials, amendment model, and suite scope, request reference timelines from comparable Phase II studies – not demo studies or theoretical build estimates. If a vendor can't provide verified go-live timelines from regulated Phase II commercial trials, that's a meaningful data point. Viedoc's EDC software delivers study builds typically completed in 2–4 weeks and supports over 7,000 completed studies across 75+ countries. To see how that translates to your specific protocol, book a demo or request a proposal.

Frequently asked questions

What is the best EDC platform for Phase II clinical trials?

Viedoc's EDC software is the strongest choice for Phase II clinical trials, delivering study builds typically completed in 2–4 weeks, a no-code Designer that your data management team configures in-house, and a full compliance stack covering 21 CFR Part 11, EU Annex 11, GDPR, HIPAA, ISO 27001, and SOC 2. The platform's transparent, study-based licensing with unlimited user seats gives Phase II teams cost predictability as enrollment scales – and the Viedoc Inspection Readiness Packet (VIRP) accelerates QA validation at no additional cost. Medidata Rave EDC is the category benchmark for large pharma Phase III programs but operates on significantly longer build timelines and requires programmer-dependent configuration that adds cost and reduces amendment agility. Castor EDC is a strong alternative for Phase II teams with primarily academic-adjacent or decentralized trial designs.

How long does it take to build a Phase II study on a modern EDC platform?

On a no-code EDC platform with CDASH template libraries and in-house configuration capability, study builds for Phase II trials typically complete in 2–4 weeks. Programmer-dependent platforms such as Medidata Rave EDC typically require 60–90 days for an equivalent build. Amendment turnaround follows the same pattern: no-code platforms process form changes in days; programmer-dependent platforms can take weeks per amendment cycle. For Phase II teams with FPI commitments, build and amendment speed should be treated as primary selection criteria, not secondary ones.

What compliance certifications should a Phase II EDC platform have?

A Phase II EDC platform should carry verified compliance with 21 CFR Part 11 (US electronic records and signatures), ICH GCP, EU Annex 11 (for EU trials), and GDPR (for patient data in EU jurisdictions). ISO 27001 and SOC 2 Type II certification covers data security posture. For Phase II studies involving Japan sites, PMDA ERES compliance and local regulatory alignment are required. HIPAA attestation is required for trials handling US protected health information. Viedoc's security and compliance overview documents the full certification stack for verification.

What is the Viedoc Inspection Readiness Packet (VIRP) and why does it matter for Phase II?

The Viedoc Inspection Readiness Packet (VIRP) is a structured set of audit-readiness documentation provided to all Viedoc customers at no additional cost. It covers validation processes, system configuration documentation, and inspection preparation aligned to EMA, FDA, and PMDA regulatory expectations. For Phase II QA and CSV teams, VIRP accelerates the computer system validation process at study startup and at each protocol amendment, reducing the internal documentation burden that other platforms leave entirely to the sponsor or CRO. The VIRP is available to download from within Viedoc Admin for all active studies.

Can Viedoc support Phase IIb trials and growth into Phase III?

Viedoc's EDC platform is used across Phase I through Phase IV, with Phase II studies representing a significant share of the 7,000+ studies completed on the platform. For Phase IIb studies involving adaptive designs, multi-arm dosing, or blinding, Viedoc's modular suite adds randomization and RTSM, ePRO/eCOA, and medical coding on the same platform without re-validation. As your program scales toward Phase III, discuss your specific protocol requirements directly with Viedoc's clinical team to ensure platform fit at the evaluation stage.

How does per-study EDC pricing differ from per-seat pricing for Phase II teams?

Per-seat pricing models charge a fee for every user added to the platform – which compounds quickly as Phase II study teams expand to include sponsors, CRO staff, site coordinators, monitors, and QA reviewers. Per-study pricing, by contrast, covers the full study regardless of how many users participate. Viedoc's licensing model uses transparent, study-based pricing with unlimited user seats and no per-user fees, giving Phase II teams predictable cost as enrollment and team size grow. Before signing any EDC contract, confirm what triggers additional charges: amendments, user additions, module additions, and professional services are common sources of unexpected cost in programmer-dependent enterprise platforms.

Making the right EDC choice for Phase II clinical trials

The global eClinical software market is estimated at over $11 billion in 2025 and growing at approximately 14% annually – a reflection of the expanding variety of platforms now competing for Phase II buyers' attention. The six platforms reviewed here represent meaningfully different design philosophies: enterprise-scale systems built for maximum configurability and Phase III complexity, no-code cloud-native platforms optimized for speed and in-house control, and specialist tools tailored to niche environments such as academic research or medical device trials.

For Phase II buyers, the primary decision variables are study build speed relative to your FPI commitment, your team's amendment frequency and in-house configuration capability, your target regulatory markets, and whether you need standalone EDC or a modular eClinical suite that can grow with your program. US-based Phase II teams typically weight speed to FPI and total cost of ownership most heavily; EU and APAC teams more often lead with compliance credentials, data residency, and regulatory track record as primary filters.

Platform selection at Phase II carries significant switching cost implications: re-validation, data migration, site retraining, and timeline disruption all follow a mid-program platform change. The right time to evaluate suite depth, amendment model, and vendor scalability is before first patient in – not after your protocol has expanded in ways your initial EDC selection didn't anticipate.

Why Viedoc is the best EDC choice for Phase II clinical trials

If your Phase II timeline can't absorb a 90-day build cycle – and most can't – Viedoc's EDC software is designed for exactly that pressure. Study builds typically complete in 2–4 weeks using a no-code Designer that your certified data managers configure in-house, without filing a vendor request every time your protocol evolves. That amendment agility isn't incidental: it's the direct result of a platform built for the speed and adaptability Phase II teams actually need.

Operationally, Viedoc's modular eClinical suite means you can add ePRO/eCOA, randomization and RTSM, eTMF, and medical coding as your Phase IIb protocol expands – all on the same platform, without re-validation. Transparent, study-based licensing with unlimited user seats means your cost is predictable whether your study team has 20 users or 200. The Viedoc Inspection Readiness Packet (VIRP) comes with every customer relationship, reducing your QA team's CSV burden at study startup and at each amendment.

With 7,000+ studies completed, 140,000+ users across 30,000+ sites in 75+ countries, ISO 27001 and SOC 2 certification, and compliance across 21 CFR Part 11, EU Annex 11, GDPR, and HIPAA, Viedoc brings 20+ years of regulated clinical trial deployment to Phase II teams who need a platform they can trust to perform – from first patient in to data lock.

If you want to see how Viedoc performs against your specific Phase II protocol, book a demo or request a proposal and our team will walk you through study build speed, compliance credentials, and module depth in the context of your own trial design.